(Reuters) – The European Medical Agency on Wednesday recommended authorization of Moderna Inc’s COVID-19 vaccine tailored towards targeting the Omicron sub-variants BA.4 and BA.5 for 12 and above ages.
The European Commission has already approved Moderna’s vaccine targeting Omicron BA.1 last month.
(Reporting by Khushi Mandowara; Editing by Maju Samuel)
